You are here

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

Last updated on May 24, 2019

FOR MORE INFORMATION
Study Location
MHAT Trimontium OOD
Plovdiv, , 4000 Bulgaria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients aged ≥18 years old at the time of enrollment

2. Patients who are prescribed CT-P13 or Remicade for the treatment of rheumatoid
arthritis, ankylosing spondylitis, and psoriatic arthritis prescribed according to the
corresponding summary of product characteristics (SmPC and Product Monograph) as
determined by the investigator

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Any reported contraindications for Inflectra according to the SmPC or Product
Monograph

2. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its
excipients or other murine proteins, at the time of enrollment

NCT02605642
Pfizer
Completed
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Psoriatic Arthritis
NCT03486457
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
NCT03992781
All Genders
Ankylosing Spondylitis
NCT03502616
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now